WebSelect search scope, currently: articles+ all catalog, articles, website, & more in one search; catalog books, media & more in the Stanford Libraries' collections; articles+ journal articles & other e-resources WebMar 8, 2012 · We found that PARP inhibitors reduced the viability of cohesin-depleted cells suggesting that PARP inhibitors may be effective for the treatment of tumors containing cohesin mutations. ... The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Mol Oncol 5(4): 387–393. View Article
Pharmacologic Induction of BRCAness in -Proficient Cancers: …
WebApr 14, 2024 · The concept of “BRCAness” was first described in 2004 to define the situation in which a homologous recombination repair (HRR) defect in a tumor relates to and … WebFeb 26, 2016 · Olaparib (Astra Zeneca) The idea of synthetic lethality has led to the use of single agent PARP inhibitors in BRCA deficient cancers. Olaparib (AZD 2281) is an oral PARP inhibitor that has shown activity in ovarian and breast tumors with known BRCA mutations and was the first FDA approved drug in this class [].The first hint of clinical … newport meadows christiana
Opinion: PARP inhibitors in cancer—what do we still need to know?
WebApr 13, 2024 · USP1 (ubiquitin-specific peptidase 1) is a synthetic lethal protein of HRD (homologous recombination deficient) tumors. As a highly selective USP1 inhibitor, SP-002 has significant anticancer activity against HRD tumors as a single drug or in combination with PARP inhibitors in preclinical in vitro studies. WebThe genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to cancer. Already there are promising indications, from clinical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in … WebJul 8, 2024 · In 2005, 2 groups described the synthetic lethal interaction between PARP inhibition and BRCA1 or BRCA2 mutation, ... Several DDR inhibitors are undergoing testing in preclinical or clinical trials, however the application of these inhibitors in synthetic lethality needs to be extensively investigated. newport media inc products